{
    "organizations": [],
    "uuid": "8718736ff63a22b75e2d630d53bfed94c397adec",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-synergy-pharmaceuticals-reports-q1/brief-synergy-pharmaceuticals-reports-q1-loss-per-share-0-15-idUSASC0A1MC",
    "ord_in_thread": 0,
    "title": "BRIEF-Synergy Pharmaceuticals Reports Q1 Loss Per Share $0.15",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Synergy Pharmaceuticals Inc:\n* SYNERGY PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE\n* Q1 SALES $8.6 MILLION * Q1 EARNINGS PER SHARE VIEW $-0.16 — THOMSON REUTERS I/B/E/S\n* Q1 REVENUE VIEW $11.1 MILLION — THOMSON REUTERS I/B/E/S * LOWERING PROJECTED TOTAL ADJUSTED OPERATING EXPENSE (NON-GAAP) GUIDANCE FOR 2018 TO BE IN RANGE OF $165 MILLION - $175 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-11T04:34:00.000+03:00",
    "crawled": "2018-05-11T12:44:32.073+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "synergy",
        "pharmaceutical",
        "inc",
        "synergy",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "business",
        "update",
        "q1",
        "sale",
        "million",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "q1",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "lowering",
        "projected",
        "total",
        "adjusted",
        "operating",
        "expense",
        "guidance",
        "range",
        "million",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}